# RRM2

Source: https://onco.cc/targets/rrm2/  
OnCo record `rrm2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.

## Summary

Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Gemcitabine. Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.00, clinical 0.99).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ribonucleotide reductase regulatory subunit M2; Ribonucleoside-diphosphate reductase subunit M2; FLJ25102; C2orf48
- Tags: cancer-genes-wave
- Symbol: RRM2
- Class: enzyme
- Biology: Provides the precursors necessary for DNA synthesis. Catalyses the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides. Inhibits Wnt signalling. Location: Cytoplasm; Nucleus (UniProt). Locus 2p25.1 (HGNC).
- Where found: Lung cancer: Open Targets association 0.62 with lung cancer (MONDO_0008903); Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059); Breast cancer: Open Targets association 0.61 with breast cancer (MONDO_0007254); Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908); Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Ovarian cancer: Open Targets association 0.59 with ovarian cancer (MONDO_0008170)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; CIViC holds 1 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10452: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10452
- UniProt P31350: https://www.uniprot.org/uniprotkb/P31350/entry
- NCBI Gene 6241: https://www.ncbi.nlm.nih.gov/gene/6241
- Ensembl ENSG00000171848: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000171848

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/rrm2.json